The Value of Quantitative Susceptibility Mapping and Morphometry in the Differential Diagnosis of Parkinsonism

References

1. 1.↵
   1. Postuma RB,
   2. Berg D,
   3. Stern M, et al

   . MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015;30:1591–601 doi:10.1002/mds.26424 pmid:26474316

   CrossRefPubMed
2. 2.↵
   1. Wenning GK,
   2. Stankovic I,
   3. Vignatelli L, et al

   . The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord 2022;37:1131–48 doi:10.1002/mds.29005 pmid:35445419

   CrossRefPubMed
3. 3.↵
   1. Höglinger GU,
   2. Respondek G,
   3. Stamelou M

   ; Movement Disorder Society-endorsed PSP Study Group, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 2017;32:853–64 doi:10.1002/mds.26987 pmid:28467028

   CrossRefPubMed
4. 4.↵
   1. Dickson DW

   . Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2012;2:a009258 doi:10.1101/cshperspect.a009258 pmid:22908195

   Abstract/FREE Full Text
5. 5.↵
   1. Massey LA,
   2. Micallef C,
   3. Paviour DC, et al

   . Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 2012;27:1754–62 doi:10.1002/mds.24968 pmid:22488922

   CrossRefPubMed
6. 6.↵
   1. Meijer FJA,
   2. van Rumund A,
   3. Fasen BACM, et al

   . Susceptibility-weighted imaging improves the diagnostic accuracy of 3T brain MRI in the work-up of parkinsonism. AJNR Am J Neuroradiol 2015;36:454–60 doi:10.3174/ajnr.A4140 pmid:25339647

   Abstract/FREE Full Text
7. 7.↵
   1. Halliday GM,
   2. Holton JL,
   3. Revesz T, et al

   . Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011;122:187–204 doi:10.1007/s00401-011-0852-9 pmid:21720849

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Paviour DC,
   2. Price SL,
   3. Jahanshahi M, et al

   . Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain 2006;129:1040–49 doi:10.1093/brain/awl021 pmid:16455792

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Nicoletti G,
   2. Fera F,
   3. Condino F, et al

   . MR imaging of middle cerebellar peduncle width: differentiation of multiple system atrophy from Parkinson disease. Radiol 2006;239:825–30 doi:10.1148/radiol.2393050459 pmid:16714464

   CrossRefPubMed
10. 10.↵
    1. Williams DR,
    2. Holton JL,
    3. Strand C, et al

    . Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 2007;130:1566–76 doi:10.1093/brain/awm104 pmid:17525140

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Paviour DC,
    2. Price SL,
    3. Stevens JM, et al

    . Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2005;64:675–79 doi:10.1212/01.WNL.0000151854.85743.C7 pmid:15728291

    Abstract/FREE Full Text
12. 12.↵
    1. Tsuboi Y,
    2. Slowinski J,
    3. Josephs KA, et al

    . Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2003;60:1766–69 doi:10.1212/01.wnl.0000068011.21396.f4 pmid:12796528

    Abstract/FREE Full Text
13. 13.↵
    1. Fearnley JM,
    2. Lees AJ

    . Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114(5):2283–301 doi:10.1093/brain/114.5.2283 pmid:1933245

    CrossRefPubMed
14. 14.↵
    1. Ide S,
    2. Murakami Y,
    3. Futatsuya K, et al

    . Usefulness of olfactory bulb measurement in 3D-FIESTA in differentiating Parkinson disease from atypical parkinsonism. AJNR Am J Neuroradiol 2024;45:1141–52 doi:10.3174/ajnr.A8275 pmid:38871365

    Abstract/FREE Full Text
15. 15.↵
    1. Wang Z-L,
    2. Yuan L,
    3. Li W, et al

    . Ferroptosis in Parkinson’s disease: glia–neuron crosstalk. Trends Mol Med 2022;28:258–69 doi:10.1016/j.molmed.2022.02.003 pmid:35260343

    CrossRefPubMed
16. 16.↵
    1. Biondetti E,
    2. Santin MD,
    3. Valabrègue R, et al

    . The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease. Brain 2021;144:3114–25 doi:10.1093/brain/awab191 pmid:33978742

    CrossRefPubMed
17. 17.↵
    1. Depierreux F,
    2. Parmentier E,
    3. Mackels L, et al

    . Parkinson’s disease multimodal imaging: f -DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI. NPJ Parkinsons Dis 2021;7:57 doi:10.1038/s41531-021-00199-2 pmid:34238927

    CrossRefPubMed
18. 18.↵
    1. Boelmans K,
    2. Holst B,
    3. Hackius M, et al

    . Brain iron deposition fingerprints in Parkinson’s disease and progressive supranuclear palsy. Mov Disord 2012;27:421–27 doi:10.1002/mds.24926 pmid:22290788

    CrossRefPubMed
19. 19.↵
    1. Wang Y,
    2. Butros SR,
    3. Shuai X, et al

    . Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 2012;33:266–73 doi:10.3174/ajnr.A2765 pmid:22051807

    Abstract/FREE Full Text
20. 20.↵
    1. Frosini D,
    2. Ceravolo R,
    3. Tosetti M, et al

    . Nigral involvement in atypical parkinsonisms: evidence from a pilot study with ultra-high field MRI. J Neural Transm (Vienna) 2016;123:509–13 doi:10.1007/s00702-016-1529-2 pmid:26943945

    CrossRefPubMed
21. 21.↵
    1. Meijer FJ,
    2. Steens SC,
    3. van Rumund A, et al

    . Nigrosome-1 on susceptibility weighted imaging to differentiate Parkinson’s disease from atypical parkinsonism: an in vivo and ex vivo pilot study. Pol J Radiol 2016;81:363–69 doi:10.12659/PJR.897090 pmid:27559425

    CrossRefPubMed
22. 22.↵
    1. Langkammer C,
    2. Schweser F,
    3. Krebs N, et al

    . Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. NeuroImage 2012;62:1593–99 doi:10.1016/j.neuroimage.2012.05.049 pmid:22634862

    CrossRefPubMed
23. 23.↵
    1. Goetz CG,
    2. Fahn S,
    3. Martinez-Martin P, et al

    . Movement disorder society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007;22:41–47 doi:10.1002/mds.21198 pmid:17115387

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Hoehn MM,
    2. Yahr MD

    . Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42 doi:10.1212/wnl.17.5.427 pmid:6067254

    FREE Full Text
25. 25.↵
    1. Cosottini M,
    2. Frosini D,
    3. Pesaresi I, et al

    . MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology 2014;271:831–38 doi:10.1148/radiol.14131448 pmid:24601752

    CrossRefPubMed
26. 26.↵
    1. Mazzucchi S,
    2. Frosini D,
    3. Costagli M, et al

    . Quantitative susceptibility mapping in atypical Parkinsonisms. Neuroimage Clin 2019;24:101999 doi:10.1016/j.nicl.2019.101999 pmid:31539801

    CrossRefPubMed
27. 27.↵
    1. Quattrone A,
    2. Nicoletti G,
    3. Messina D, et al

    . MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008;246:214–21 doi:10.1148/radiol.2453061703 pmid:17991785

    CrossRefPubMed
28. 28.↵
    1. Massey LA,
    2. Jäger HR,
    3. Paviour DC, et al

    . The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology 2013;80:1856–61 doi:10.1212/WNL.0b013e318292a2d2 pmid:23616165

    Abstract/FREE Full Text
29. 29.↵
    Parkinson’s Disease and Movement Disorders Group. Neurology Division, Chinese Medical Association, China, and Specialized Committee on Parkinson’s Disease and Movement Disorders, Neurologists Branch, Chinese Physicians Association (CPA). Chinese clinical diagnostic criteria for progressive supranuclear palsy. Chinese J Neurol 2016;49:272–76
30. 30.↵
    1. Prodoehl J,
    2. Li H,
    3. Planetta PJ, et al

    . Diffusion tensor imaging of Parkinson’s disease, atypical parkinsonism, and essential tremor. Mov Disord 2013;28:1816–22 doi:10.1002/mds.25491 pmid:23674400

    CrossRefPubMed
31. 31.↵
    1. Mitchell T,
    2. Archer DB,
    3. Chu WT, et al

    . Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum Brain Mapp 2019;40:5094–107 doi:10.1002/hbm.24760 pmid:31403737

    CrossRefPubMed
32. 32.↵
    1. Krismer F,
    2. Beliveau V,
    3. Seppi K, et al

    . Automated analysis of diffusion-weighted magnetic resonance imaging for the differential diagnosis of multiple system atrophy from Parkinson’s disease. Mov Disord 2021;36:241–45 doi:10.1002/mds.28281 pmid:32935402

    CrossRefPubMed
33. 33.↵
    1. Reimão S,
    2. Ferreira S,
    3. Nunes RG, et al

    . Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson’s disease. Eur J Neurol 2016;23:368–74 doi:10.1111/ene.12838 pmid:26518135

    CrossRefPubMed
34. 34.↵
    1. Ahmed Z,
    2. Asi YT,
    3. Sailer A, et al

    . The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 2012;38:4–24 doi:10.1111/j.1365-2990.2011.01234.x pmid:22074330

    CrossRefPubMed
35. 35.↵
    1. Yamamoto A,
    2. Shin R-W,
    3. Hasegawa K, et al

    . Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer’s disease. J Neurochem 2002;82:1137–47 doi:10.1046/j.1471-4159.2002.t01-1-01061.x pmid:12358761

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Hill JM

    . Iron concentration reduced in ventral pallidum, globus pallidus, and substantia nigra by GABA-transaminase inhibitor, gamma-vinyl GABA. Brain Res 1985;342:18–25 doi:10.1016/0006-8993(85)91348-4 pmid:4041811

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Christine CW,
    2. Aminoff MJ

    . Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance. Am J Med 2004;117:412–19 doi:10.1016/j.amjmed.2004.03.032 pmid:15380498

    CrossRefPubMed
38. 38.↵
    1. Graham JM,
    2. Paley MN,
    3. Grünewald RA, et al

    . Brain iron deposition in Parkinson’s disease imaged using the PRIME magnetic resonance sequence. Brain 2000;123:2423–31 doi:10.1093/brain/123.12.2423 pmid:11099445

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Devos D,
    2. Labreuche J,
    3. Rascol O

    ; FAIRPARK-II Study Group, et al. Trial of deferiprone in Parkinson’s Disease. N Engl J Med 2022;387:2045–55 doi:10.1056/NEJMoa2209254 pmid:36449420

    CrossRefPubMed
40. 40.↵
    1. Zeng X,
    2. An H,
    3. Yu F, et al

    . Benefits of iron chelators in the treatment of Parkinson’s disease. Neurochem Res 2021;46:1239–51 doi:10.1007/s11064-021-03262-9 pmid:33646533

    CrossRefPubMed
41. 41.↵
    1. Möller L,
    2. Kassubek J,
    3. Südmeyer M, et al

    . Manual MRI morphometry in Parkinsonian syndromes. Mov Disord 2017;32:778–82 doi:10.1002/mds.26921 pmid:28150443

    CrossRefPubMed
42. 42.↵
    1. Nigro S,
    2. Morelli M,
    3. Arabia G, et al

    . Magnetic resonance parkinsonism index and midbrain to pons ratio: which index better distinguishes progressive supranuclear palsy patients with a low degree of diagnostic certainty from patients with Parkinson disease? Parkinsonism Relat Disord 2017;41:31–36 doi:10.1016/j.parkreldis.2017.05.002 pmid:28487107

    CrossRefPubMed
43. 43.↵
    1. Williams DR,
    2. Lees AJ

    . Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8:270–79 doi:10.1016/S1474-4422(09)70042-0 pmid:19233037

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Marxreiter F,
    2. Lambrecht V,
    3. Mennecke A, et al

    . Parkinson’s disease or multiple system atrophy: potential separation by quantitative susceptibility mapping. Ther Adv Neurol Disord 2023;16:17562864221143834 doi:10.1177/17562864221143834 pmid:36846471

    CrossRefPubMed
45. 45.↵
    1. Sjöström H,
    2. Granberg T,
    3. Westman E,
    4. Svenningsson P

    . Quantitative susceptibility mapping differentiates between parkinsonian disorders. Parkinsonism Relat Disord 2017;44:51–57 doi:10.1016/j.parkreldis.2017.08.029 pmid:28886909

    CrossRefPubMed
46. 46.↵
    1. Chougar L,
    2. Pyatigorskaya N,
    3. Lehéricy S

    . Update on neuroimaging for categorization of Parkinson’s disease and atypical parkinsonism. Curr Opin Neurol 2021;34:514–24 doi:10.1097/WCO.0000000000000957 pmid:34010220

    CrossRefPubMed
47. 47.↵
    1. Pellecchia MT,
    2. Barone P,
    3. Mollica C, et al

    . Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. Mov Disord 2009;24:689–96 doi:10.1002/mds.22440 pmid:19117367

    CrossRefPubMed
48. 48.↵
    1. Sjöström H,
    2. Granberg T,
    3. Westman E, et al

    . Quantitative susceptibility mapping differentiates between parkinsonian disorders. Parkinsonism Relat Disord 2017;44:51–57 doi:10.1016/j.parkreldis.2017.08.029 pmid:28886909

    CrossRefPubMed
49. 49.↵
    1. Oba H,
    2. Yagishita A,
    3. Terada H, et al

    . New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005;64:2050–55 doi:10.1212/01.WNL.0000165960.04422.D0 pmid:15985570

    Abstract/FREE Full Text